Two Drug Molecules Identified That Trigger Myelin Regrowth in MS Models
Similar Articles
Researchers Restore Memory in Dementia Models by Fixing Mitochondrial Activity
Anti-Aging Drug Combination Damages Nerve Insulation in Mice Study
Scientists Develop Drug Method to Boost Natural Killer Cells Against Multiple Cancers
Researchers Identify New Enzyme Target That Reduces Alzheimer's Plaques in Lab Studies
Experimental Compounds Show Promise in Reducing Brain Inflammation Linked to Alzheimer's
Researchers at the University of Helsinki have identified two separate drug molecules that trigger myelin regrowth in models of Multiple Sclerosis (MS). Both molecules reduce neuroinflammation and cross the blood-brain barrier, working through different mechanisms to achieve similar results. The findings, published in late 2025, are based on animal and cell models, and no remyelination drug candidate has yet entered human clinical trials.
Facts First
- Two drug molecules trigger myelin regrowth in Multiple Sclerosis (MS) disease models.
- Both molecules reduce neuroinflammation and cross the blood-brain barrier in laboratory animals.
- The molecules work through different mechanisms but yielded similar results.
- Current MS treatments suppress the immune response but do not repair existing damage.
- No remyelination drug candidate has yet entered clinical trials for humans.
What Happened
Tapani Koppinen at the University of Helsinki identified two separate drug molecules that triggered myelin regrowth in Multiple Sclerosis (MS) disease models. Both molecules reduced neuroinflammation and crossed the blood-brain barrier in laboratory animals. The molecules work through different mechanisms but yielded similar results. The first approach targets the unfolded protein response to increase and accelerate remyelination in tissue showing MS-like damage, according to results published in Molecular Therapy in October 2025. The second approach uses a different molecule to change the composition of scar tissue to allow remyelination to proceed, with work published in Neuropharmacology in November 2025.
Why this Matters to You
If you or someone you know has MS, this research represents a potential new direction for treatment. Current treatments suppress the immune response but do not repair existing damage to the protective sheath around nerve fibers. These findings may lead to therapies that could restore insulation to nerve fibers, potentially improving function. However, the findings are currently based on animal and cell models, and no remyelination drug candidate has yet entered clinical trials for humans, meaning any potential treatment is likely years away.
What's Next
The two identified molecules will need to undergo further preclinical testing before they could be considered for human trials. Their different mechanisms may offer complementary approaches to overcoming the barriers to repair in later-stage MS, where scar tissue formation blocks remyelination. This research could eventually lead to the first treatments that repair existing damage for the approximately three million people worldwide with MS.